Search

Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire

Six creative Connecticut students turn aspiring ideas into inventive innovation

Learn about the 2023 Connecticut Invention Convention winners.

Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US

BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.

How to Apply

To apply for the program, please complete one of the following application forms and follow the directions on the application form submission

The Core of our Leitbild

Click here to find out more about Boehringer Ingelheim's core values and mission statement, highlighting our key business focuses.

Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia

The Importance of Drug Discovery | R&D | Boehringer Ingelheim US

Research & Development

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Open Innovation at Boehringer Ingelheim

BI increases commitments to sustainable development

At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

Innovation in CardioMetabolic Disease Research

Partnering in Retinal Health

Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.

Technologies

We are expanding our global network of technology partners. Learn more about partnering with us.

S&P Animal Health Partnering Oct 2023

Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach

Regulatory Affairs

Read more on BI's two-year fellowship within Regulatory Affairs. The Fellow will obtain in-depth and hands-on experience in regulatory strategy.

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Fornovo San Giovanni (Bidachem)

Founded in 1981, Fornovo San Giovanni serves both – Human Pharma and Animal Health

Advocating for More Patient-Centered Mental Health Care

BI Beyond Borders: Science, Collaboration, Geography | BI US

Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers